Cancer Discov. 2019 Oct;9(10):OF3. doi: 10.1158/2159-8290.CD-NB2019-103. Epub 2019 Aug 30.
According to results from a phase I/II trial, the investigational WEE1 inhibitor adavosertib combined with gemcitabine and radiation is well tolerated and may benefit patients with locally advanced pancreatic adenocarcinoma by increasing both systemic and local disease control.
根据一项 I/II 期临床试验的结果,研究性 WEE1 抑制剂adavosertib 联合吉西他滨和放疗具有良好的耐受性,并可能通过增加全身和局部疾病控制,使局部晚期胰腺腺癌患者受益。